Award Number:  W81XWH-08-1-0380

TITLE:  Elucidating the Tumor Suppressive Role of SLITs in Maintaining the Basal Cell Niche

PRINCIPAL INVESTIGATOR:  Lindsay Hinck

CONTRACTING ORGANIZATION:  University of California
                            Santa Cruz, CA 95064

REPORT DATE:  July 2009

TYPE OF REPORT:  Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
                Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT:  (Check one)

    ✓  Approved for public release; distribution unlimited

    Distribution limited to U.S. Government agencies only; report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
The research performed over the last twelve months is based on the hypothesis that SLIT/ROBO1 signaling regulates interactions between myoepithelial and luminal epithelial cells, and that loss of this activity results in the destabilization of the basal cell niche. We analyzed the Slit2−/−;Slit3−/− and Robo1−/− null mammary gland phenotypes using a battery of immunohistochemical markers and identified discohesive, hyperplastic lesions with basal characteristics. Adhesive contacts between cells appear largely normal. The lesions have a basal character as they contain excess basal cells, but they are not triple negative (ER−, PR−, HER2−). We performed serial transplantation of knockout tissue and discovered that the Slit2−/−;Slit3−/− tissue displays a longevity phenotype. Mammosphere assays revealed significantly more CK8− positive cells in Slit2−/−;Slit3−/− tissue. These data suggest that loss of Slit2 and Slit3 spares cell divisions along the luminal lineage, allowing the outgrowth of luminal-enriched, lateral bud structures that persist for 5–10 additional generations. Thus disruption of this basal niche, by knocking out Slit2 and Slit3, results in hyperplastic lesions and deregulation of stem/progenitor cell populations. Our research promises to provide insight into the mechanisms by which normal stem/progenitor cells are regulated, leading to potential insights into how they may be deregulated upon cancerous transformation.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4 -9</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>9</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>9 -10</td>
</tr>
<tr>
<td>Conclusion</td>
<td>10</td>
</tr>
<tr>
<td>References</td>
<td>10-11</td>
</tr>
<tr>
<td>Appendices</td>
<td>11-20</td>
</tr>
</tbody>
</table>
INTRODUCTION:

Myoepithelial cells have recently been termed the “natural tumor suppressor” of the breast because they maintain breast tissue integrity by organizing the cells in contact with them, including cells in the breast stem cell niche, located between the myoepithelial and luminal epithelial cell layers. SLITs are a family of secreted proteins that were originally identified as axon guidance cues in the nervous system. Numerous studies have demonstrated the epigenetic inactivation of Slits and Robos in multiple types of cancer, including breast, an observation supported by our studies (Marlow et al., 2008). The research we performed over the past 12 months under the auspices of an IDEA Award is based on the hypothesis that SLIT/ROBO1 signaling regulates interactions between myoepithelial and luminal epithelial cells, and that loss of this activity results in the destabilization of the basal cell niche and subsequent formation of ductal lesions with basal characteristics. Over the past 12 months, we have investigated this hypothesis as outlined in the Statement of Work by analyzing the Slit2-/-;Slit3-/- and Robo1-/- null mammary gland phenotypes using a battery of immunohistochemical markers. On the advise of our pathology consultant, we also performed serial transplantation of the knock-out tissue. Our data show that loss of Slits results in hyperplastic lesions composed of unpolarized cells. Adhesive contacts between cells appear largely normal. The lesions have a basal character in that they contain excess basal cells, but they are not triple negative (ER–, PR–, HER2–). The Slit2-/-;Slit3-/- tissue displays a longevity phenotype that may be due to deregulation of at least one population of stem/progenitor cells.

BODY:

In initiating the work outlined in our funded application, we first considered our reviewers’ comments. Even though the application received an excellent score, the reviewers noted one minor weakness — that we did not have a pathologist examine the Slit2-/-;Slit3-/- and Robo1-/- lesions. To address this concern, we obtained a histopathological evaluation from Dr. Robert Cardiff who directs the UC Davis Mutant Mouse Pathology Laboratory and has extensive experience analyzing mouse models of breast cancer. As described in our funded proposal, there are extensive lesions in Slit2-/-;Slit3-/- and Robo1-/- glands, but they are not palpable and there is no evidence of metastasis. Dr. Cardiff described these lesions as hyperplastic and discohesive, with basal characteristics. He also described the surrounding stroma as desmoplastic and containing substantial immune infiltrates. Thus, Slit2-/-;Slit3-/- and Robo1-/- lesions model an early stage of breast transformation, rather than the fully transformed phenotype obtained, for example, by overexpressing MMTV-oncogenes.

Dr. Cardiff suggested we serially transplant the tissue to test whether cells are immortalized. We have established two Slit2-/-;Slit3-/- lines; one senesced at generation 11 and the second is currently at generation 13. The contralateral wild type glands senesced, as expected, at generation 5. Lesions in the knockout outgrowths become more severe with successive transplant generations. These data, together with other data collected in the past year (see below), suggest that the observed longevity phenotype arises from a stem cell defect, and we propose to pursue the characterization of this phenotype. This will not change the scope of our research, which is focused on understanding the role of SLITs in maintaining the basal cell niche, but it will require a refinement of our technical approaches.

Outline of proposed research for the first 12 months from the Statement of Work:

Aim I: Characterize the hyperplastic lesions observed in Slit2-/-;Slit3-/- and Robo1-/- mammary glands.

Task 1: Define the identity of the disorganized cells in ducts and document degree of polarity retained, (months 2-8)

a. Generate tissue by transplantation
b. Cross-section occluded ducts and double stain for CK14 (Covance) and the following markers: ERα (SCBT), HER1 (R&D), and HER2 (Chemicon) and quantify % disorganized cells with basal phenotype.

c. Document polarity status of disorganized cells. Cross-section occluded ducts and double stain for CK14 to mark basal cells and the following polarity markers: ZO-1 (Zymed), E-cadherin (Zymed), β-catenin (SCBT), laminin (Sigma) beta1-integrin (Charles Streuli). Evaluate level of laminin staining at ductal/stromal interface and for presence in ductal lumen.

d. Animals required: a-c) 16 immunocompromised hosts with tissue from 2 independently derived lines of tissue. Use 8 animals /fixation protocol.

Task 2: Identify the hyperproliferating cells, (months 6-12)

a. Generate tissue by transplantation.

b. Cross-section occluded ducts and mount alternate sections on separate slides. Double stain one set for CK14 /Ki67 and another for CK8 (DSHB) / Ki67 (SCBT). Quantify proliferative pool in each fraction

---

**Figure 1: Immunohistochemical analysis of a variety of markers.** Sections of tissue were stained with antibodies directed against the indicated markers as described in (Marlow et al., 2008). For all markers, we did not observe dramatic differences between +/+ and Slit2/-;Slit3/- tissue as shown by quantitative analysis for the steroid hormone receptors.
and the % basal cells in the occluded ductal space. Significance of the data will be evaluated using unpaired, two-tailed Mann-Whitney tests.
c. Animals required: a-b) 12 immunocompromised hosts with tissue from 2 independently derived lines of tissue.

Task 5: Downregulate Robo1 expression in normal human mammary cell lines, (months 1-12)

a. MCF7 cells will be characterized for their expression of Slits and Robo using western blots and immunohistochemistry.
b. MCF7 cells transfected with RNAi to Robo1(SCBT) screened for ROBO1 knockdown by Western blot (anti-DUTT1, Dr. Rabbitts) and used in Transwell and Matrigel invasion assays. Changes in migration and invasion phenotype will be be quantified relative to control siRNA transfected cells. Significance of the data will be evaluated using Student’s t-test.

Results and interpretations:

Aim I: Characterize the hyperplastic lesions observed in Slit2-/-;Slit3-/ and Robo1-/ mammary glands.

Task 1: Define the identity of the disorganized cells in ducts and document degree of polarity retained, (months 2-8): The basic characterization of the hyperplastic lesions observed in Slit2-/-;Slit3-/ and Robo1-/- mammary glands was published in October of 2008 in Cancer Research and the DoD was acknowledged for their support of this research. As outlined in the Statement of Work, we also performed double immunohistochemistry with CK14 and the following antibodies: Task1b -- ERα, HER1, HER2; Task 1c – ZO-1, E-cadherin, P-cadherin, β−catenin, laminin and beta1-integrin (Figure 1). We did not see significant differences between wild type and Slit2-/-;Slit3-/- tissue in the levels of estrogen or progesterone receptor. Analysis of cell adhesion and polarity proteins did not reveal differences in the levels of β-catenin and E-cadherin along the membrane, nor were there changes in the matrix component laminin or β-integrin. Hyperplastic cells filling the lumen appear to be unpolarized, having lost the polarity marker Z0-1 along the apical surface, although hyperplastic cells lining luminal areas appear properly polarized.

Because these analyses did not reveal dramatic differences between wild type and Slit2-/-;Slit3-/ tissue, we also performed immunoblotting experiments to evaluate total protein levels (Figure 2). In these analyses, we observed changes in total protein, including elevation in Her1/EGFR and, as expected in hyperproliferating cells, cyclin D1 in Slit2-/-;Slit3-/-, compared to +/+ tissue. We also observed reductions in Her2 and E-cadherin in Slit2-/-;Slit3-/-, compared to +/+ tissue. This later result was interesting in light of a paper, investigating
Slit/Robo1 signaling in MCF7 breast cancer cells, and showing increased E-cadherin at cell borders in cells overexpressing Slit2 (Prasad et al., 2008). Even though our immunohistochemical analysis did not reveal dramatic changes in the levels or localization of cadherin/catenin adhesion system, our immunoblotting observation in a loss-of-function setting correlates with this result of Prasad and colleagues in a gain-of-function setting. One explanation is that we may have missed, using immunohistochemistry, subtle changes in E-cadherin expression if they occurred in a subset of epithelial cells in vivo. Our immunoblot may have picked up this downregulation, although a caveat to the immunoblotting approach is that it was performed on whole gland, which includes adipocytes and blood vessels and, consequently, the observed changes by Western analysis may not occur within the epithelium. The ability to localize changes to the epithelium is the reason we proposed an immunohistochemical approach in our application. To investigate further, we are performing a more detailed immunohistochemical analysis to evaluate whether there are changes in the expression or localization of E-cadherin or β-catenin in a subset of Slit2-/-;Slit3-/-, compared to +/-, mammary cells within the epithelium.

Summary Task1:

Hyperplastic lesions in the Slit2-/-;Slit3-/- glands appear to retain many of the characteristics of +/- tissue. The cells appear to retain relatively normal contacts, both between cells (cell-cell) and between cells and the extracellular environment (cell-ECM). Knockout cells in the middle of a lesion lose polarity, but polarity is retained when these cells are at the edge of a lumen.

Based on the recommendation of our pathologist, we performed serial transplantation analysis and discovered that Slit2-/-;Slit3-/- glands display enhanced longevity. We have transplanted two, independently-derived lines of tissue past the usual age of senescence at generation (G) 5; one to G11 and the second, which is still growing, to G13. These aged Slit2-/-;Slit3-/- outgrowths have a different morphology compared to younger outgrowths (Figure 3). Wild type and early generation Slit2-/-;Slit3-/- outgrowths have ductal trees with many primary ducts arrayed in a regular branching pattern. In contrast, by G5-G10 Slit2-/-;Slit3-/- outgrowths have only a few, short primary ducts with no formal branches, only unusual lateral bud structures.

Figure 3: Whole Mounts of +/- and Slit2-/-;Slit3-/- Outgrowths
Epithelial fragments were transplanted into clear fat pads of immunocompromised mice. A. +/- outgrowths senesce at G5. B. Slit2-/-;Slit3-/- outgrowths senescence at G11. After G5, a change in phenotype can be seen. Arrows point to primary duct, arrowheads to lateral ductal buds. Scale bar = 1mm.
**Task 2: Identify the hyperproliferating cells, (months 6-12):** We performed double immunohistochemistry to identify the cells — basal or luminal — that are proliferating in tissue collected at several different transplant generations (Figure 3). We did not observe a difference in the number of proliferating basal cells between Slit2-/-;Slit3-/- and +/- outgrowths. Thus, even though the cells are hyperproliferating, it does not appear as if this rapid cell growth favors one population of cells over another. This indicates that both the basal and luminal cells hyperproliferate, and that the basal-like phenotype observed in the Slit2-/-;Slit3-/- knockout is due to overall hyperproliferation of cells and not selective proliferation of the basal cell population.

To take this analysis one step further, we assessed the stem/progenitor cell populations in Slit2-/-;Slit3-/-, compared to +/-, outgrowths by performing mammosphere assays on cells collected from different generations of outgrowths (Dontu et al., 2003) (Figure 4). Assays on G3 tissue revealed similar numbers of progenitor cells in +/- and Slit2-/-;Slit3-/- outgrowths. However, Slit2-/-;Slit3-/- G5 tissue contained significantly more stem/progenitor cells compared to senescing, +/- tissue (Fig. 4). Immunofluorescent analyses of these mammospheres revealed significantly more CK8-positive cells in Slit2-/-;Slit3-/- tissue (Figure 5), indicating a bias toward luminal progenitors.

**Figure 4: Quantification of proliferating basal cells.**

Tissue sections were stained for basal and proliferation markers. The total number and double-positive cells were counted in 20 fields of view. We observe no significant difference in the number of proliferating basal cells over three generations in +/- compared to Slit2-/-;Slit3-/- tissue.

### Task 2:

- **+/+**
- **Slit2-/-;Slit3-/-**

<table>
<thead>
<tr>
<th>Generation</th>
<th>% of proliferating epithelial cells positive for basal marker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>3</td>
<td>20</td>
</tr>
<tr>
<td>5</td>
<td>30</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>3</td>
<td>20</td>
</tr>
<tr>
<td>5</td>
<td>30</td>
</tr>
</tbody>
</table>

**Summary Task 2:**

Together, our data suggest that loss of Slit2 and Slit3 spares cell divisions along the luminal lineage, allowing the outgrowth of luminal-enriched, lateral bud structures that persist for 5-10 additional generations. This is an intriguing stem cell phenotype and it suggests that the hypothesis outlined in our IDEA grant is correct — that SLITs contribute in important ways to tissue integrity by maintaining and organizing the breast stem cell niche that is located between the myoepithelial and luminal epithelial layer. Disruption of this niche, by knocking out Slit2 and Slit3, results in hyperplastic lesions and deregulation of stem/progenitor cell populations.

**Task 5: Downregulate Robo1 expression in normal human mammary cell lines, (months 1-12):**

These experiments were performed and published in Cancer Research (Marlow et al., 2008). We discovered that downregulating Robo1 in MCF7 cells results in a hyperplastic, discohesive phenotype, similar to the phenotype observed in Slit2-/-;Slit3-/- and Robo1-/- mammary outgrowths.
Recommended changes in future work to better address the research topic:

We performed an analysis of a variety of markers, as described in the Statement of Work. However, we did not observe dramatic differences between Slit2-/-;Slit3-/- and wild type tissue. Based on the recommendation of our pathologist, Dr. Robert Cardiff, we performed serial transplant analysis and discovered an intriguing increase in the longevity of Slit2-/-;Slit3-/- outgrowths. This observation supports the overarching hypothesis of our Idea Award that loss of Slits contributes to tumor progression by disrupting stem cells that reside in the basal cell niche. We think that future effort should focus on identifying and quantifying stem cell populations in successive generations of Slit2-/-;Slit3-/- outgrowths by mammosphere and fluorescent cell sorting assays.

KEY RESEARCH ACCOMPLISHMENTS:

- Generated Slit2-/-;Slit3-/- and Robo1-/- mammary glands by transplantation
- Evaluated the hyperplastic lesions in Slit2-/-;Slit3-/- and Robo1-/- mammary glands by performing immunohistochemical analyses using a battery of antibodies
- Published paper in Cancer Research identifying the tumor suppressive function of Slits in breast/mammary gland
- Identified a potential stem cell phenotype—increased longevity in Slit2-/-;Slit3-/- outgrowths

REPORTABLE OUTCOMES:

Paper:


Abstracts:
Rebecca Marlow, Mikhail Binnewies, Phyllis Strickland, Camilla Forsberg, Dean Li and Lindsay Hinck. Loss of Slit expression within the epithelium promotes angiogenesis and neoplastic transformation in breast. Keystone Symposia: Extrinsic Control of Tumor Genesis and Progression. March 15-20, 2009.


CONCLUSIONS:

Evidence is growing that myoepithelial cells function as “natural tumor suppressors” because they organize tissue structure, including cells in the breast stem cell niche, and generate the barrier between epithelium and stroma by secreting the basal lamina. Over the first year of this IDEA Award, my laboratory has characterized, as outlined in the Statement of Work, the basal-like hyperplastic lesions that occur in mammary glands harboring loss-of-function mutations in Slit2 and Slit3. Some of these data were published in Cancer Research and the rest is presented in this annual report. Evaluating a number of parameters by immunohistochemical analysis, we did not observe significant differences between Slit2-/-;Slit3-/- and +/- tissue. Slit2-/-;Slit3-/- lesions express estrogen and progesterone receptors and HER2/neu at levels similar to wild type. Therefore, these lesions do not fit the triple negative (ER–, PR–, HER2–) classification. We did not observe significant changes in the levels and localization of E-cadherin or β-catenin within the mammary epithelium, although we are still exploring potential subtle effects of Slit loss on these proteins in individual cells.

Based on the advice of Dr. Cardiff, our pathologist, we made a major discovery, by performing serial transplantation assays, that loss of Slits results in an enhanced longevity phenotype. We previously demonstrated that loss of Slits destabilizes the interactions between myoepithelial and luminal cell layers—a region comprising the stem cell niche (Strickland et al., 2006). Tissue-specific stem cells are found in most, if not all, adult tissues. These cells function to fuel organ growth and regeneration throughout life. These cells are particularly important in breast which undergoes stereotyped cycles of cell growth and differentiation under the influence of estrus and pregnancy hormones. In breast tumors, the stem cell hypothesis posits that cancer stem cells, a small population of self-renewing cells within a tumor, are responsible for breast cancer progression and recurrence. This suggests that the targets of malignant transformation are normal stem/progenitor cells. Many laboratories are attempting to identify and characterize cancer stem cells. These efforts will be greatly aided by a better understanding of normal stem cells: their identification in situ and elucidation of their regulation during normal development. Our data suggest that SLITs regulate at least one population of stem cells. Our continued research to characterize the Slit2-/-;Slit3-/- longevity phenotype under the auspices of the DoD promises to provide insight into the mechanisms by which normal stem/progenitor cells are regulated, leading to potential insights into how they may be deregulated upon cancerous transformation.

REFERENCES:


**APPENDICES:**

- pdf of our paper in *Cancer Research*

**SUPPORTING DATA:** Figures are embedded in the text.
SLITs Suppress Tumor Growth In vivo by Silencing Sdf1/Cxcr4 within Breast Epithelium

Rebecca Marlow,1 Phyllis Strickland,1 Ji Shin Lee,3 Xinyan Wu,3 Milana PeBenito,1 Mikhail Binnewies,1 Elizabeth K. Le,1 Angel Moran,1 Hector Macias,1 Robert D. Cardiff,2 Saraswati Sukumar,3 and Lindsay Hinck1

1Department of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, California; 2University of California Davis Center of Comparative Medicine, Davis, California; and 3Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Abstract

The genes encoding Slits and their Robo receptors are silenced in many types of cancer, including breast, suggesting a role for this signaling pathway in suppressing tumorigenesis. The molecular mechanism underlying these tumor-suppressive effects has not been delineated. Here, we show that loss of Slits, or their Robo1 receptor, in murine mammary gland or human breast carcinoma cells results in coordinate up-regulation of the Sdf1 and Cxcr4 signaling axis, specifically within mammary epithelium. This is accompanied by hyperplastic changes in cells and desmoplastic alterations in the surrounding stroma. A similar inverse correlation between Slit and Cxcr4 expression is identified in human breast tumor tissues. Furthermore, we show in a xenograft model that Slit overexpression down-regulates CXC4R and dominantly suppresses tumor growth. These studies classify Slits as negative regulators of Sdf1 and Cxcr4 and identify a molecular signature in hyperplastic breast lesions that signifies inappropriate up-regulation of key prometastatic genes. [Cancer Res 2008;68(19):7819–27]

Introduction

The multistep model for breast carcinogenesis postulates that invasive carcinoma arises by way of intermediate hyperplastic lesions that progress in severity through stages of atypia to in situ and finally invasive carcinoma. It is generally recognized that there are clinically significant differences between various hyperplastic lesions, with some containing cellular and molecular changes that confer higher risk of progression to invasive disease. Pathologists identify clinically relevant differences later in disease progression, but early breast lesions are not well defined and further subclassification of their tumor potential by morphologic criteria is likely to be impossible. Consequently, assessing the potential risks associated with premalignant breast disease will rely on refining our understanding of the molecular signatures that confer increased risk of progression from epithelial hyperplasia to invasive carcinoma.

Up-regulation of CXCR4 is an example of one molecular change in breast cancer cells that is associated with poor prognosis (1, 2). Its role in directing metastasizing breast cancer cells to target sites is well established (3). Little is known, however, about the role of CXCR4 during breast cancer progression, although it is up-regulated early during cellular transformation (1, 4), along with SDF1 (5), which is produced by cancer-associated fibroblasts (CAF) and is in the local environment (6, 7). Recent studies have identified roles for this signaling pathway in primary breast tumors (8, 9), and in this context, one possibility is that signaling through the CXCR4/SDF1 axis drives proliferation, conferring selective advantage to cells as they transform into metastasizing carcinomas. Several mechanisms up-regulate CXCR4 during tumor metastasis (10–13), but there is little information about mechanisms regulating the SDF1/CXCR4 chemokine axis in organs at early stages of transformation.

SLITs (Slit1, Slit2, and Slit3) are a family of secreted proteins that mediate positional interactions between cells and their environment during development by signaling through ROBO receptors (Robo1, Robo2, Robo3, and Robo4; ref. 14). SLIT/ROBO signaling, however, is not restricted to development, and loss of these cues likely plays an important role during tumor progression. Slits and Robos are considered candidate tumor suppressor genes because their promoters are frequently hypermethylated in epithelial cancers (15–18). In ~ 50% of sampled human breast tumors, Slit2 or Slit3 gene expression is silenced (15, 19).

Cross-talk between SLIT/ROBO and CXCR4/SDF1 signaling has been observed in several systems, with the regulatory effect occurring downstream of the receptors and involving modulation of intra- or intercellular signaling intermediates. In leukocytes and human breast cancer cell lines, SLIT impedes SDF1-induced chemotaxis (20, 21). In breast cancer cells, this deterring effect occurs via SLIT-mediated inhibition of SDF1-induced activation of signaling pathways involved in motility (21). Similarly, in the nervous system, a reciprocal regulation of SLIT-mediated axonal repulsion by SDF1 is exerted through modulation of cyclic nucleotide signaling intermediates (22). These studies show an intriguing interrelationship between these signaling axes but do not address the consequences of losing the function of one of these signaling systems, such as occurs in breast cancer cell lines during tumor progression when Slit expression is silenced.

Here, we investigate the consequences of losing SLIT/ROBO1 signaling in murine mammary gland, human breast cancer cells, and human tumors. We identify Sdf1 and Cxcr4 as critical targets of SLIT/ROBO1 regulation. Exploiting the ability to transplant knockout mammary epithelium into host mammary fat pads, we determine the compartment, epithelial or stromal, in which SLIT/ROBO1 signaling occurs, and how loss of signaling in one location leads to alterations across the epithelial/stromal boundary. Finally, we explore the tumor-suppressive capabilities of Slits using a xenograft model of human breast cancer.
Materials and Methods

Clinical samples. Frozen or formalin-fixed paraffin-embedded tissue specimens were collected at Johns Hopkins University (Baltimore, MD). All human tissue was collected using protocols approved by the Institutional Review Board. Informed consent was obtained from each individual who provided tissue linked with clinical data.

Animals. The study conformed to guidelines set by University of California at Santa Cruz animal care committee (Chancellor’s Animal Research Committee). Mouse Slit2, Slit3, and Robo1 nulls were generated at California at Santa Cruz animal care committee (Chancellor’s Animal Research Committee). Tissue fragments from the resulting outgrowths were contralaterally transplanted into precleared fat pads of athymic nude mice (25). Tissue was fixed in 4% paraformaldehyde. Immunohistochemistry. Immunostaining was scored according to percentage positive cells (P) and staining intensity (I). Score equals P × I. P scores 0 (none), 1 (<1%), 2 (1–10%), 3 (10–30%), 4 (30–60%), and 5 (>60%). I scores 0 (none), 1 (weak), 2 (intermediate), and 3 (strong).

RNA interference. Small interfering RNA (siRNA) directed against Robo1 was from Santa Cruz Biotechnology. pSecTagB-ROBO1-Myc and selected in zeocin (Invitrogen).

siRNA transfection. MCF7 cells were transiently transfected using Robo1 siRNA (Santa Cruz Biotechnology) and Lipofectamine 2000 (Invitrogen) according to the manufacturers’ instructions. For three-dimensional culture, the “on-top” method was used (28). For luciferase assay, 48 h before harvest, cells were cotransfected with pGL-CXCR4(–375) (F-luciferase) and pRL-TK (R-luciferase). Cells were lysed using passive lysis buffer and assay was carried out in triplicate using the Dual-Luciferase Assay System (Promega) and Wallac Victor Luminometer (Perkin-Elmer Life Sciences) according to the manufacturers’ instructions. F-luciferase activity was normalized to R-luciferase activity (transfection efficiency).

Cell lines, DNA constructs, and antibodies. MCF7 and MDA-MB-231 cells were maintained in DMEM supplemented with 10% FCS. pGL-CXCR4(–375) contains CXCR4 between –357 and +51 relative to the transcription site followed by the luciferase gene (12). pCRII-SDF1 (for riboprobes) contains 538-nucleotide fragment of the mouse Sdf1 cDNA (27). Mouse image clone 3385804 (American Type Culture Collection). Small interfering RNA (siRNA) directed against Robo1 was from Santa Cruz Biotechnology. pSecTagB-hSlit3-C-myc was from Dr. Roy Bicknell (University of Birmingham, Birmingham, United Kingdom). The following antibodies were used: anti-CK14 (AF64, Covance), anti-SMA (1A4, Sigma), anti-Ki67 (Santa Cruz Biotechnology), anti-CXCR4 (Abcam), anti-SDF1 (Santa Cruz Biotechnology), anti-SLIT3 (Chemicon), anti-SLIT2 (Chemicon), anti-HA (Dr. Doug Kellog, University of California, Santa Cruz, CA), anti-Myc (9E10), anti-ROBO1 (Abcam), and anti-extracellular signal-regulated kinase (Santa Cruz Biotechnology).

Generation of stable cell lines. MDA-MB-231 cells were transfected with pSecTagB-Slit2-HA and pSecTagB-Slit3-Myc and selected in zeocin (Invitrogen). n = 3 lines were generated expressing SLIT2-HA and n = 2 lines expressing SLIT3-Myc.

Tumor generation. Stable cell lines (10^6 cells) were injected into precleared fat pads of nude mice. Tumor volume was calculated using the formula length width^2/2. Tumor size was measured using a caliper every 5 d, colonies were photographed (5×) and percentage of disorganized structures was counted. Representative images of colonies are shown. Scale bar, 10 μm. Columns, mean percentage; bars, SD. **, P < 0.001, ANOVA. RNAi, RNA interference. D, lack of ROBO1 increases the cell proliferation index. Columns, mean percentage of Ki67+ cells; bars, SD. **, P < 0.001, ANOVA.

Figure 1. Loss of Slit2 and Slit3 expression in mammary epithelium leads to the formation of hyperplastic disorganized lesions. A, lack of SLIT in the epithelium leads to lesion formation. Immunostaining with anti-CXCR4 on longitudinal sections and cross-sections through +/- and Slit2−/−;Slit3−/− mammary outgrowths. Arrows, ductal myoepithelial cell layer; arrowheads, CK14-positive cells abnormally located in the lumen. Red bar, condensed desmoplastic stroma. L, lumen. B, lack of SLIT leads to hyperplasia. Representative lesion with dashed line indicating epithelial/stromal interface. Arrowheads, Ki67+ cells. Columns, mean percentage [n = 3 animals at 12 wk of age, 15 fields of view/animal (5×)]; bars, SD. ***, P < 0.001, unpaired t test. C, lack of ROBO1 leads to a disorganized phenotype in three-dimensional culture. After transfection, MCF7 cells were grown in Matrigel. After 5 d, colonies were photographed (5×) and percentage of disorganized structures was counted. Representative images of colonies are shown. Scale bar, 10 μm. Columns, mean percentage; bars, SD. ***, P < 0.0001, ANOVA. RNAi, RNA interference. D, lack of ROBO1 increases the cell proliferation index. Columns, mean percentage of Ki67+ cells; bars, SD. **, P < 0.001, ANOVA.
Western blotting. Western blotting was performed using standard procedures (29). Band intensity was scanned using Typhoon 9410 imager and quantified using ImageQuant software.

Quantitative real-time reverse transcription-PCR analysis. Real-time reverse transcription-PCR (RT-PCR) analysis was done as previously described (30). Data were first analyzed using the Sequence Detector Software SDS 2.0 (Applied Biosystems). Results were calculated and normalized relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control. All of the PCR assays were done in triplicate, and mean values were in figures.

In situ hybridization. In situ hybridization was carried out as described previously (23, 25).

Primary cell isolation. Primary mammary epithelial cells were prepared from mild collagenase and dispase digestion, as described (23). Cells were plated overnight and then trypsinized and placed onto Matrigel-coated coverslips.

Chemotaxis assay. Chemotaxis was examined as described before (29). Phase-contrast images were acquired at 0 and 60 min. The change in cell area in the directed quadrant was calculated using ImageJ.

Statistical analysis. We used factorial design ANOVA, unpaired t tests, or Mann-Whitney tests to analyze data as appropriate. Significant ANOVA procedures (29). Band intensity was scanned using Typhoon 9410 imager (GAPDH) control. All of the PCR assays were done in triplicate, and mean normalized relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control. Activity was measured in triplicate. Activities were normalized for transfection efficiency. Columns, mean relative luciferase activity; bars, SE. **, P = 0.0095, Mann-Whitney test. D, loss of SLIT/ROBO signaling in MCF7 cells leads to increased levels of CXCR4 protein. Representative immunoblots (n = 4). Numbers, CXCR4 band intensity.

Results

Loss of Slit or Robo1 in mammary epithelium leads to the formation of hyperplastic, disorganized lesions. Given the expanding role of SLITs in epithelial biology, we hypothesized a tumor-suppressive function for Slits in breast. We previously showed that two Slit family members, Slit2 and Slit3, are expressed in murine mammary gland (23). The homozygous Slit2−/− mutation causes perinatal lethality. Therefore, to investigate the consequence of its loss in mature mammary gland, we generated Slit2−/−;Slit3−/− outgrowths by contralateral transplantation of knockout and wild-type anlage into cleared fat pads of immunocompromised mice (24).

We examined mature Slit2−/−;Slit3−/− mammary outgrowths for morphology. Compared with the open lumens and organized bilayers of ducts in control outgrowths, Slit2−/−;Slit3−/− ducts displayed striking abnormalities (Fig. 1A). The phenotype was 100% penetrant, with ~30% of ducts having lesions extending between 0.3 and 5.0 mm. We categorized the lesions as mild and severe. Mild lesions contained cells in the luminal space (10.1% ± SE 1.9; n = 621 ducts; 5 outgrowths), and many of these cells were peeled away from the myoepithelial layer, similar to an adhesive defect previously described in Ntr1−/−;Slit2−/− glands (23). In severe lesions (17.8% ± SE 8.1; n = 621 ducts; 5 outgrowths), ductal lumens were occluded with a disorganized mass of cells (Fig. 1A). These excess cells suggested disrupted growth control due to either increased proliferation and/or decreased apoptosis. We labeled proliferating cells and observed a significant increase in the percentage of Ki67+ cells in Slit2−/−;Slit3−/−, compared with +/+ ducts (Fig. 1B). This increase is responsible for the excess cells

Figure 2. Loss of Slit2 and Slit3 causes up-regulation of CXCR4 in mouse mammary gland and human MCF7 cells. A, in Slit2−/−;Slit3−/− outgrowths, CXCR4 protein expression is localized to epithelia, with desmoplastic stroma between lesions. Representative immunostaining with anti-CXCR4 on +/+ and Slit2−/−;Slit3−/− mammary outgrowths. Arrowheads, positive epithelial cells. Red bar, condensed desmoplastic stroma. Scale bar, 20 μm. CXCR4 immunostaining was scored according to positivity and staining intensity and plotted on a vertical scatter plot. Red bars, average score. Significantly more CXCR4 staining is seen in Slit2−/−;Slit3−/− outgrowths, *** P < 0.0001, Mann-Whitney. B, Cxcr4 mRNA is specifically present in the epithelium of Slit2−/−;Slit3−/− outgrowths. In situ hybridization on +/+ and Slit2−/−;Slit3−/− outgrowths using antisense probes reveals Cxcr4 mRNA in Slit2−/−;Slit3−/−, but not +/+ cells. Arrowheads, positive epithelial cells. Sense probes show little or no background staining. Scale bar, 20 μm. L, lumen. C, loss of SLIT/ROBO signaling in MCF7 cells leads to up-regulation of Cxcr4 gene expression. Cells were treated with control or Robo1 siRNA and then cotransfected with pGL-CXCR4(-375), which contains the Cxcr4 promoter region coupled to the F-luciferase gene and pRL-TK (R-luciferase). Cells were lysed after 36 h and luciferase activity was measured in triplicate. Activities were normalized for transfection efficiency. Columns, mean relative luciferase activity; bars, SE. **, P = 0.0095, Mann-Whitney test. D, loss of SLIT/ROBO signaling in MCF7 cells leads to increased levels of CXCR4 protein. Representative immunoblots (n = 4). Numbers, CXCR4 band intensity.
As was the case for Slit2, the penetrance of the phenotype was 100%, with we used the MCF7 line that retains several characteristics SLIT/ROBO1 signaling was disrupted in human breast cells, displaying lesions that extended between 0.3 and 5.0 mm. Loss of function phenotype using intact glands. Ducts in the gland (23).

To investigate whether a similar phenotype occurred when SLIT/ROBO1 signaling was disrupted in human breast cells, we used the MCF7 line that retains several characteristics of differentiated mammary epithelium, including expression of Slit2, Slit3, and Robo1 (data not shown; ref. 31). Cells were treated with Robo1 siRNA to down-regulate SLIT/ROBO1 signaling (Supplementary Fig. S2) and then cultured in Matrigel. MCF7 cells formed smooth, nonpolarized colonies without central lumens. In contrast, the siRNA-treated colonies were large outgrowths and showed elevated proliferation leading to hyperplastic glands (Fig. 1B). Together, these data show that a consequence of Loss of Robo1 is decreased expression in tumors, whereas CXCR4 levels increase. Normal breast, but its expression is decreased in tumors, whereas CXCR4 levels increase. Normal breast, whereas CXCR4 is expressed at very low levels compared with normal breast. In these tumors, this elevation corresponded with significantly reduced expression of Slit2 or Slit3. Columns, mean relative expression; bars, SE. Slit2 versus CXCR4: **, P < 0.01; Slit3 versus CXCR4: ***, P < 0.001, ANOVA. C, SLIT expression is decreased in tumors, whereas CXCR4 levels increase. Normal breast, DCIS, and IDC tissue sections were immunostained with anti-SLIT2, anti-SLIT3, and anti-CXCR4. Representative images are shown. Scale bar, 100 μm. D, immunostained sections were scored according to cell percentage positivity and staining intensity. Scores were plotted on a vertical scatter plot. Black bars, average score. Both SLIT2 (**, P = 0.01, ANOVA) and SLIT3 (***, P < 0.0001, ANOVA) exhibit decreased expression in DCIS and IDC compared with normal breast. In contrast, CXCR4 is expressed at very low levels in normal breast, but its expression increases in DCIS and IDC (**, P = 0.0005, ANOVA).
One candidate is CXCR4 because it is expressed early during breast tumorigenesis (1, 4), and blocking its expression or function inhibits breast tumor growth (8, 9). Western blots of whole gland lysates showed elevated CXCR4 expression in Slit2\(^{-/-}\);Slit3\(^{-/-}\) compared with +/+ tissue (Supplementary Fig. S3). Immunohistochemistry revealed CXCR4 expression in a large fraction of cells in Slit2\(^{-/-}\);Slit3\(^{-/-}\) epithelium, with little or no expression in +/+ epithelium (Fig. 2A). We also observed condensed and desmoplastic stroma surrounding these CXCR4-positive lesions (Fig. 2A). Because CXCR4 is regulated by transcriptional and posttranscriptional mechanisms, we performed in situ hybridization studies and observed Cxcr4 in Slit knockout, but not wild-type, epithelium (Fig. 2B). A transcriptional mechanism also occurred in Robo1 siRNA-treated MCF7 cells because we observed increased Cxcr4

![Diagram](https://www.aacrjournals.org/7823/CancerRes2008;68:(19).October1,2008)

**Figure 4.** Loss of Slit expression results in coordinate up-regulation of SDF1 and the formation of desmoplastic stroma. A, Slit2\(^{-/-}\);Slit3\(^{-/-}\), but not +/+ cells respond to a point source of SDF1. Primary epithelial cells were prepared from outgrowths and placed in stable liquid gradients of SDF1 (29). Phase-contrast images were acquired at 0 and 60 min. Using ImageJ, the change in cell area in the source quadrant was calculated. Columns, mean percentage change (n = 7); bars, SE. *, P = 0.0018, Mann-Whitney. B, SDF1 protein is present in the stroma surrounding Slit2\(^{-/-}\);Slit3\(^{-/-}\) outgrowths. Representative immunostaining with anti-SDF1 on +/+ and Slit2\(^{-/-}\);Slit3\(^{-/-}\) mammary outgrowths. Red bars, average score. Significantly more SDF1 staining is seen in Slit2\(^{-/-}\);Slit3\(^{-/-}\) compared with +/+ tissue (Supplementary Fig. S3). Immunohistochemistry revealed CXCR4 expression in a large fraction of cells in Slit2\(^{-/-}\);Slit3\(^{-/-}\) epithelium, with little or no expression in +/+ epithelium (Fig. 2A). We also observed condensed and desmoplastic stroma surrounding these CXCR4-positive lesions (Fig. 2A). Because CXCR4 is regulated by transcriptional and posttranscriptional mechanisms, we performed in situ hybridization studies and observed Cxcr4 in Slit knockout, but not wild-type, epithelium (Fig. 2B). A transcriptional mechanism also occurred in Robo1 siRNA-treated MCF7 cells because we observed increased Cxcr4

![Diagram](https://www.aacrjournals.org/7823/CancerRes2008;68:(19).October1,2008)

**Figure 4.** Loss of Slit expression results in coordinate up-regulation of SDF1 and the formation of desmoplastic stroma. A, Slit2\(^{-/-}\);Slit3\(^{-/-}\), but not +/+ cells respond to a point source of SDF1. Primary epithelial cells were prepared from outgrowths and placed in stable liquid gradients of SDF1 (29). Phase-contrast images were acquired at 0 and 60 min. Using ImageJ, the change in cell area in the source quadrant was calculated. Columns, mean percentage change (n = 7); bars, SE. *, P = 0.0018, Mann-Whitney. B, SDF1 protein is present in the stroma surrounding Slit2\(^{-/-}\);Slit3\(^{-/-}\) outgrowths. Representative immunostaining with anti-SDF1 on +/+ and Slit2\(^{-/-}\);Slit3\(^{-/-}\) mammary outgrowths. Dotted lines, epithelial/stromal interface. Open arrowheads, positive staining in stroma; arrows, epithelial cells expressing SDF1. Scale bar, 20 μm. SDF1 immunostaining was scored according to positivity and intensity. Scores were plotted on a vertical scatter plot. Red bars, average score. Significantly more SDF1 staining is seen in Slit2\(^{-/-}\);Slit3\(^{-/-}\) outgrowths. *, P = 0.018, Mann-Whitney. C, SDF1 attracts macrophages. a, representative images of F4/80 staining in fat pads containing BSA versus SDF1 Elvax pellets. The number of F4/80\(^+\) cells surrounding pellets was counted and expressed as the number of F4/80\(^+\) cells per μm\(^2\). Columns, average; bars, SD. *, P = 0.0086, unpaired t test. Macrophages surround Slit2\(^{-/-}\);Slit3\(^{-/-}\) ducts. b, representative images of F4/80 staining in +/+ versus Slit2\(^{-/-}\);Slit3\(^{-/-}\) tissue. Duct length was measured and the number of F4/80\(^+\) cells was counted (ImageJ software). Columns, average; bars, SD. ***, P < 0.0001, unpaired t test (n = 3 animals, 10 fields of view/animal). Stroma surrounding Slit2\(^{-/-}\);Slit3\(^{-/-}\) ducts is desmoplastic. c, representative images of Masson’s trichrome staining of +/+ versus Slit2\(^{-/-}\);Slit3\(^{-/-}\) tissue. Red bar, width of stroma. Longitudinal images of ducts were taken and duct length and positively stained areas were measured (ImageJ software). Columns, average; bars, SD. ***, P < 0.0001, unpaired t test. Scale bar, 20 μm. D, Sdf1 mRNA is specifically present in subpopulations of elongated stromal cells (open arrowheads) and epithelial cells (closed arrowheads) in Slit2\(^{-/-}\);Slit3\(^{-/-}\) outgrowths. In situ hybridization on +/+ and Slit2\(^{-/-}\);Slit3\(^{-/-}\) outgrowths using antisense probes reveals Sdf1 mRNA in Slit2\(^{-/-}\);Slit3\(^{-/-}\), but not +/+ cells. Sense probes show no or little background staining. Scale bar, 20 μm.
reporter gene activity and increased levels of CXCR4 in treated, compared with control, cells (Fig. 2C and D). Together, our results show that SLIT/ROBO1 signaling negatively regulates Cxcr4 expression, with loss of this regulation leading to elevated levels of Cxcr4 in murine tissue and human breast cancer cells.

If Slits silence Cxcr4 in normal breast, we hypothesize that loss of Slits in tumors will correspond with elevated Cxcr4. To investigate, we analyzed microarray data sets from human breast tumor samples available at Oncomine.org (32) and found an inverse correlation between Slit and Cxcr4 expression (Fig. 3A). We confirmed this by performing quantitative RT-PCR on a panel of human tumors; in 68% of tumors with elevated Cxcr4 expression, Slit or Slit3 levels were significantly reduced compared with their expression in normal tissue (Fig. 3B). We further verified these observations at the protein level using immunohistochemistry on samples of normal breast, ductal carcinoma in situ (DCIS), and infiltrating ductal carcinoma (IDC; Fig. 3C and D). Again, there were robust levels of SLIT2 and SLIT3 in normal tissue that significantly decreased with increasing tumor grade. In contrast, and as previously shown (1, 4), little or no CXCR4 was detectable in normal breast, but its expression significantly increased with higher tumor grade.

**Loss of Slit expression results in coordinate up-regulation of SDF1.** Although CXCR4 is up-regulated in the vast majority of sampled premalignant lesions, studies on human breast cancer cell lines have suggested that it is only active in metastatic cells (33). To evaluate CXC4R activity in Slit2−/−; Slit3−/− cells, we performed chemotaxis assays. Slit2−/−; Slit3−/− cells did not exhibit robust migration as expected of primary cells harvested from premalignant tissue but instead responded to SDF1 by reorganizing their cell membrane and sending membrane projections toward a point source (Fig. 4A). Wild-type cells were unresponsive to SDF1. This result suggested that CXC4R expressed on Slit2−/−; Slit3−/− cells is active and reacts to its ligand.

This raised the question of whether SDF1 surrounded Slit2−/−; Slit3−/− lesions because recent studies have placed it in the tumor microenvironment (6, 7). We found abundant SDF1 expression in the epithelium and the surrounding stroma of knockout, but not wild-type, tissue (Fig. 4B). The presence of SDF1 is consistent with the histopathologic diagnosis that noted the infiltration of immune cells within desmoplastic stroma surrounding Slit2−/−; Slit3−/− lesions. Macrophages, which express CXC4R, represent a major component of immune infiltrates surrounding tumors and play a key role in promoting the angiogenic switch during malignant transition (34). To determine whether macrophages are attracted to SDF1, we implanted point sources of SDF1 or vehicle (BSA) into wild-type mammary glands (Fig. 4C, a). Significantly more macrophages (F4/80+) infiltrated into the tissue containing SDF1 or vehicle (BSA) compared with control (Fig. 4C, b). Together, our results show that SLIT/ROBO1 signaling negatively regulates Cxcr4 expression, with loss of this regulation leading to elevated levels of Cxcr4 in murine tissue and human breast cancer cells.
performed F4/80 immunohistochemistry on Slit2\(^{-/-}\);Slit3\(^{-/-}\) and control tissue and found a significant increase in macrophages surrounding knockout tissue (Fig. 4C, b). We also evaluated the stromal expression of collagen, a major constituent of desmoplastic stroma (Fig. 4C, c). Stroma surrounding Slit2\(^{-/-}\);Slit3\(^{-/-}\) epithelium contained significantly more condensed, collagenous stroma, compared with +/+ , consistent with the histopathologic analysis. To define the cellular source of SDF1, we performed in situ hybridization analyses and discovered Sdf1 in a fraction of epithelial cells and in a subset of elongated stromal cells that are likely to be fibroblasts based on their morphology (Fig. 4D). Thus, both CXC4 and SDF1 are initially up-regulated in the epithelium, as has been recently observed in a xenograft model of DCIS (5). A local source of SDF1 may function to transform myoepithelial cells into CAFs or to recruit CAFs from circulating cells (35).

Epithelial regulation of CXC4/SDF1 chemokine signaling axis. Together, the data show that loss of Slit expression leads to the coordinate up-regulation of Cxcr4 in epithelia and Sdf1 in both epithelium and stroma. This suggests that SLIT/ROBO signaling keeps SDF1/CXC4 expression in check, but the regulatory networks may be complicated. Slit genes are expressed in the epithelia, but they encode a secreted cue that may act on any cell type expressing ROBO1 receptors. During mammary development, ROBO1 is expressed on myoepithelial cells (23), but as the gland matures, we observed its expression in a switch to include a subpopulation of luminal cells (Fig. 5A). ROBO1 was also expressed on stromal fibroblasts (Fig. 5A). Consequently, loss of Slit expression could regulate Sdf1 and Cxcr4 independently by disrupting ROBO1 signaling in both the stromal and epithelial compartments. Alternatively, loss of Slit/ROBO1 signaling in just one compartment could up-regulate Sdf1 and Cxcr4 in both compartments.

To investigate, we eliminated Slit/ROBO1 signaling selectively in the epithelial compartment by transplanting Robo1\(^{-/-}\) epithelium into wild-type stroma. In these chimeric glands, we observed disorganized, hyperplastic epithelial lesions (Fig. 5B), which were similar in phenotype, penetrance (100%), and expressivity (19.64% ± SE; 9.77; n = 669 ducts; 6 outgrowths) to those seen in Slit2\(^{-/-}\);Slit3\(^{-/-}\) transplants (Fig. 1A). We evaluated the chemokine axis and again found up-regulation of CXC4 in Robo1\(^{-/-}\) epithelium (Fig. 5C), and coordinate up-regulation of SDF1 in the surrounding +/+ stroma (Fig. 5D, a), which was desmoplastic and contained immune infiltrates similar to stroma surrounding Slit2\(^{-/-}\);Slit3\(^{-/-}\) tissue (data not shown). These data show that loss of SLIT/ROBO1 signaling in the epithelial compartment, alone, up-regulates SDF1 and CXC4. This leads to phenotypic changes similar to those occurring in Slit2\(^{-/-}\);Slit3\(^{-/-}\) transplants in which SLIT/ROBO1 signaling is disrupted in both compartments. To define the source of SDF1 in the transplanted tissue, we performed in situ hybridization studies and found Sdf1 mRNA in cell subpopulations in the epithelium and stroma (Fig. 5D, b), suggesting that loss of SLIT/ROBO1 signaling in breast epithelium at early stages of transformation both generates a local source of Sdf1 and up-regulates Cxcr4. We therefore conclude that loss of SLIT/ROBO1 signaling in the epithelium, alone, is sufficient to drive the observed morphologic and molecular changes, resulting in hyperplastic lesions, surrounded by desmoplastic stroma.

SLITs suppress CXC4 expression and inhibit tumor growth. Given that SLITs exert this regulatory function by inhibiting the expression of Sdf1 and Cxcr4 within the mammary epithelium, we wondered whether overexpression of Slit in human breast carcinoma cells would suppress Cxcr4 expression and inhibit tumor growth. Previous studies have shown that the metastatic human cell line MDA-MB-231 expresses CXC4, but not SDF1 (36), and that inhibiting CXC4 expression or function in these cells blocks primary tumor growth (8, 9). Because MDA-MB-231 cells express ROBO1 and ROBO2 (21),\(^4\) signaling through these receptors could down-regulate CXC4 expression and suppress tumor formation. To investigate, we transiently expressed Myc-Slit2

\(^4\) R. Marlow, unpublished data.
discussion

there is extensive literature on the molecular and genetic alterations that occur in invasive breast carcinoma and signify poor prognosis, but relatively little progress has been made in defining the genetic changes occurring in premalignant lesions. here, we report that loss of slit expression early during tumor progression up-regulates a key chemokin signaling axis and generates hyperplastic changes in the epithelium, along with desmoplastic changes in the stroma. expression of cxcr4 was originally thought to occur late during tumor progression, generating cells that are ready to metastasize and home to organs expressing high levels of sdf1 (3). this restricted view of cxcr4 function, however, has been called into question because 93% of studied cases of atypical ductal carcinoma display high levels of cxcr4 (4), suggesting a role for cxcr4 in mediating earlier aspects of cellular transformation. our data show that changes, loss and gain, in slit expression function as a switch in the epithelium that up-regulate and down-regulate cxcr4, leading to attendant changes in proliferation. we also show that loss of slits results in the coordinate up-regulation of sdf1 in both the epithelium and surrounding stroma and this is accompanied by changes in the local microenvironment consistent with transformation.

the importance of the tumor microenvironment is well established, but it is unclear how it is generated. our studies show that loss of slit/robo1 signaling exclusively in the epithelia is sufficient to increase expression of both ccr4 and sdf1 (fig. 5). the establishment of an initial sdf1/cxcr4 signaling loop within the epithelium is supported by recent studies using human mcf10dcis.com cells in a xenograft model (5). both cxcr4 and sdf1 are expressed at low levels in early mcf10dcis lesions. cxcr4 expression remains epithelial, but during intermediate stages of transformation, sdf1 is switched on in the activated stroma. once the ductal carcinoma becomes invasive, sdf1 expression is extinguished in the epithelia and is exclusively expressed by caf's in the activated stroma. the origin of these caf's is currently unknown. some may be transformed from normal fibroblasts by aberrant signals from cancerous epithelial cells, whereas others may be transformed after being recruited from circulating bone marrow-derived cells (35). in either case, the transformation of these cells seems to be a consequence of their interaction with the cancerous epithelium. our data raise the possibility that up-regulation of epithelial sdf1, accompanying slit loss, contributes to the recruitment and/or transformation of caf's, and supports the model that genetic changes in the tumor epithelium, alone, are sufficient to drive transformation of cells and the surrounding microenvironment (7).

our data also provide in vivo evidence that the sdf1/cxcr4 axis is fully functional within the epithelium during preinvasive stages of breast transformation and that it promotes cell survival and proliferation. we show that loss of slit/robo1 signaling results in the development of hyperplastic lesions (fig. 1) with the coordinate up-regulation of both cxcr4 and sdf1 in the mammary epithelium (figs. 2, 4, and 5). this type of autocrine stimulation of cell growth by sdf1/cxcr4 has been documented in human breast cancer cells on overexpression of sdf1 (39) and was also observed in the mcf10dcis.com cells, described above, in which intraepithelial sdf1/cxcr4 signaling gives way to signaling across the epithelial/stromal boundary as the tumor microenvironment becomes established (5). numerous pathways have been implicated in the mitogenic activity of sdf1/cxcr4 and may be responsible for the hyperplastic lesions observed in slit2−/−;slit3−/− tissue (40). we are currently investigating the pathways that drive proliferation because targeting these pathways could provide therapies that arrest cellular proliferation in early stages of transformation.

the molecular mechanism through which cells acquire sdf1 and cxcr4 expression during the evolution of tumors is unclear. at later stages of cellular transformation, cxcr4 expression is up-regulated by several mechanisms (40). our studies reveal a transcriptional mechanism during early stages of transformation that occurs within breast epithelia (figs. 2, 4, and 5). we show that slits signal through their robo1 receptor to negatively regulate ccr4 and sdf1. negative transcriptional regulation of both ccr4 and sdf1 has been shown in renal cells where hypoxia-inducible factors 1 and 2 (hif1 and hif2) are targeted for degradation by von hippel-lindau (vhl) proteins (11). it has been shown that loss of vhl leads to stabilization of hifs and subsequent up-regulation of both sdf1 and ccr4 due to the hif response elements contained in their promoters (41). hifs are frequently up-regulated during breast transformation (42) and can drive the inappropriate proliferation of cells even under conditions of normal oxygen (43). thus, hifs or vhl proteins may be targeted by slit/robo1 signaling, and we are currently investigating their expression profiles in slit2−/−;slit3−/− and robo1−/− glands.

numerous studies show epigenetic inactivation of slits in multiple types of cancer (15, 16, 18, 19), and in breast, this loss of slit also correlates with increasing tumor grade (44). our histopathologic analyses of slit2−/−;slit3−/− and robo1−/− mammary epithelium revealed hyperplastic lesions with no nuclear atypia (fig. 1), a type of lesion that can be found in ~ 30% of women with benign proliferative breast disease (45). epidemiologic studies show that identification of such lesions confers a 2-fold increase in relative risk of developing invasive breast cancer compared with women without proliferative disease. for patients diagnosed with lesions having the next stage of severity, hyperplasias with nuclear atypia, the relative risk of future invasive disease rises to ~ 5-fold and increases to 10-fold if there is also positive family history (45, 46). these numbers show that, although most patients will not develop invasive disease, a fraction will. with medical advances enabling detection of breast lesions at earlier stages, it will be crucial to develop methods that distinguish between nascent disease and normal biology because current methods relying on
morphic criteria are insufficient. Improved understanding of molecular signatures within breast lesions holds the promise of identifying those at high risk so they receive appropriate treatment while also identifying the majority who are not at risk so their medical concerns are dispelled (47). The findings presented in this report identify the loss of Slit expression as a marker of early lesions that have the potential to progress to invasive disease due to up-regulation of metastasis markers SDF1/CXCR4. We propose that these molecular alterations define a specific subclass of breast lesions whose early detection could lead to treatment strategies that prevent development of invasive disease.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References